BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22365399)

  • 1. Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.
    Li HL; Huang XP; Zhou XH; Ji TH; Wu ZQ; Wang ZQ; Jiang HY; Liu FR; Zhao T
    Biomed Environ Sci; 2011 Dec; 24(6):630-41. PubMed ID: 22365399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
    Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
    Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance].
    Li JF; Li GD; Liu WP; Wang Y; Cheng JR; Chen Y; Yang H; Tang HL; Bai YQ; Lin DG; DU LH; Peng FX; Yang YH; Zhao C
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):213-7. PubMed ID: 16776978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
    J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
    Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL
    Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
    Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ
    Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
    Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
    Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of heat shock protein 72 (Hsp72) expression and activity on stress-induced apoptosis in CD30+ NPM-ALK+ anaplastic large-cell lymphomas.
    Bonvini P; Zorzi E; Mussolin L; Pillon M; Romualdi C; Peron M; d'Amore ES; Lamant L; Rosolen A
    Leukemia; 2012 Jun; 26(6):1375-82. PubMed ID: 22289917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
    Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
    Hum Pathol; 2006 Jul; 37(7):874-82. PubMed ID: 16784988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F; Arnold MD; Frist AY; Pulford K
    Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
    Sibon D; Fournier M; Brière J; Lamant L; Haioun C; Coiffier B; Bologna S; Morel P; Gabarre J; Hermine O; Sonet A; Gisselbrecht C; Delsol G; Gaulard P; Tilly H
    J Clin Oncol; 2012 Nov; 30(32):3939-46. PubMed ID: 23045585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.
    King RL; Dao LN; McPhail ED; Jaffe ES; Said J; Swerdlow SH; Sattler CA; Ketterling RP; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Gibson SE; Ondrejka SL; Nicolae A; Macon WR; Dasari S; Parrilla Castellar E; Feldman AL
    Am J Surg Pathol; 2016 Jan; 40(1):36-43. PubMed ID: 26379151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
    Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.